DK2576782T3 - Sirna og anvendelse deraf i fremgangsmåder og sammensætninger til behandling og/eller forebyggelse af øjentilstande - Google Patents

Sirna og anvendelse deraf i fremgangsmåder og sammensætninger til behandling og/eller forebyggelse af øjentilstande Download PDF

Info

Publication number
DK2576782T3
DK2576782T3 DK11723600.0T DK11723600T DK2576782T3 DK 2576782 T3 DK2576782 T3 DK 2576782T3 DK 11723600 T DK11723600 T DK 11723600T DK 2576782 T3 DK2576782 T3 DK 2576782T3
Authority
DK
Denmark
Prior art keywords
sirna
prevention
compositions
treatment
methods
Prior art date
Application number
DK11723600.0T
Other languages
English (en)
Inventor
Marta Lopez-Fraga
Ana Isabel Jimenez
Tamara Martinez Valcarel
Original Assignee
Sylentis Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylentis Sau filed Critical Sylentis Sau
Application granted granted Critical
Publication of DK2576782T3 publication Critical patent/DK2576782T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK11723600.0T 2010-05-27 2011-05-27 Sirna og anvendelse deraf i fremgangsmåder og sammensætninger til behandling og/eller forebyggelse af øjentilstande DK2576782T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10380074A EP2390327A1 (en) 2010-05-27 2010-05-27 siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
PCT/GB2011/051007 WO2011148193A1 (en) 2010-05-27 2011-05-27 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions

Publications (1)

Publication Number Publication Date
DK2576782T3 true DK2576782T3 (da) 2019-07-01

Family

ID=42829386

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11723600.0T DK2576782T3 (da) 2010-05-27 2011-05-27 Sirna og anvendelse deraf i fremgangsmåder og sammensætninger til behandling og/eller forebyggelse af øjentilstande

Country Status (20)

Country Link
US (1) US9018183B2 (da)
EP (2) EP2390327A1 (da)
JP (2) JP6008845B2 (da)
KR (1) KR101585036B1 (da)
CN (1) CN102918157B (da)
AU (1) AU2011256978B2 (da)
CA (1) CA2800412C (da)
CY (1) CY1121787T1 (da)
DK (1) DK2576782T3 (da)
ES (1) ES2732351T3 (da)
HR (1) HRP20191144T1 (da)
HU (1) HUE044715T2 (da)
LT (1) LT2576782T (da)
MX (1) MX2012012501A (da)
PL (1) PL2576782T3 (da)
PT (1) PT2576782T (da)
RS (1) RS58912B1 (da)
SI (1) SI2576782T1 (da)
TR (1) TR201909158T4 (da)
WO (1) WO2011148193A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2726613T (pt) 2011-06-30 2018-10-26 Arrowhead Pharmaceuticals Inc Composições e métodos para inibição da expressão de genes do vírus da hepatite b
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
EP2865756A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene.
EP2865757A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene.
CN115957337A (zh) 2015-08-07 2023-04-14 箭头药业股份有限公司 乙型肝炎病毒感染的RNAi疗法
WO2017042238A1 (en) * 2015-09-08 2017-03-16 Sylentis Sau Sirna and their use in methods and compositions for inhibiting the expression of the nrarp gene
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
US20200261456A1 (en) * 2019-02-15 2020-08-20 Novartis Ag Methods for treating ocular surface pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
EP1857547B2 (en) 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
DE10322662A1 (de) 2002-11-06 2004-10-07 Grünenthal GmbH Wirksame und stabile DNA-Enzyme
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
GB0521351D0 (en) 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のsiRNAおよびその使用方法
WO2008104978A2 (en) 2007-02-28 2008-09-04 Quark Pharmaceuticals, Inc. Novel sirna structures
WO2009023025A1 (en) * 2007-08-13 2009-02-19 Board Of Trustees Of Southern Illinois University Methods for treatment and prevention of ototoxicity by sirna
CA2701845A1 (en) 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures

Also Published As

Publication number Publication date
PL2576782T3 (pl) 2019-09-30
TR201909158T4 (tr) 2019-07-22
KR101585036B1 (ko) 2016-01-13
EP2576782A1 (en) 2013-04-10
AU2011256978B2 (en) 2015-06-11
JP2013528382A (ja) 2013-07-11
JP2016198104A (ja) 2016-12-01
JP6008845B2 (ja) 2016-10-19
SI2576782T1 (sl) 2019-08-30
MX2012012501A (es) 2013-02-26
PT2576782T (pt) 2019-06-28
CN102918157B (zh) 2016-06-29
WO2011148193A1 (en) 2011-12-01
KR20130043121A (ko) 2013-04-29
HUE044715T2 (hu) 2019-11-28
US9018183B2 (en) 2015-04-28
ES2732351T3 (es) 2019-11-22
US20130079389A1 (en) 2013-03-28
CN102918157A (zh) 2013-02-06
RS58912B1 (sr) 2019-08-30
CA2800412C (en) 2019-09-17
EP2390327A1 (en) 2011-11-30
HRP20191144T1 (hr) 2019-10-04
AU2011256978A1 (en) 2012-11-15
CY1121787T1 (el) 2020-07-31
CA2800412A1 (en) 2011-12-01
LT2576782T (lt) 2019-07-10
EP2576782B1 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
DK2470191T3 (da) Fremgangsmåder og præparater til forebyggelse eller behandling af oftalmiske tilstande
DK3366307T3 (da) Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri
DK2688557T3 (da) Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
DK2776567T3 (da) Sammensætninger og fremgangsmåder til behandling af cytomegalovirus.
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
IL229239A0 (en) Crystalline forms of dimethoxy docetaxel and methods for preparing the same
DK2532680T3 (da) Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
DK2774616T3 (da) Anvendelse af roseburia i behandling og forebyggelse af fedmerelaterede sygdomme
ZA201503332B (en) Water treatment composition and method of using same
ME03766B (me) Određeni amino-pirimidini, njihove kompozicije, i metode njihove upotrebe
EP2831001A4 (en) COMPOSITION FOR THE TREATMENT OF WATER AND METHOD FOR USE
DK2413947T3 (da) Fremgangsmåder og sammensætninger til behandling af hudtilstande forbundet med vaskulær hyperreaktivitet
DK2815769T3 (da) Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet
DK2723347T3 (da) Forebyggelse og behandling af inflammationstilstande
DK2854910T3 (da) Ceramidniveauer i behandling og forebyggelse af infektioner
DK3581199T3 (da) Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis
PL3400958T3 (pl) Kompozycje i metody leczenia celiakii
DK2661274T3 (da) Sammensætninger og fremgangsmåder med aloepolysaccharider
DK2800575T3 (da) Behandling af subarachnoidalblødning og iskæmi
DK2854822T3 (da) Polysaccharidsammensætninger og fremgangsmåder til anvendelse
DK2702992T3 (da) Anvendelse af melatonin til behandling af og/eller forebyggelse af mucositis
PT2576782T (pt) Arnsi e utilização dos mesmos em métodos e composições para o tratamento e/ou prevenção de condições oculares
DK3434276T3 (da) Fremgangsmåde og farmaceutisk sammensætning til anvendelse i behandlingen af kræft
EP2618824A4 (en) METHOD AND COMPOSITIONS FOR TREATING DIABETES AND DYSLIPIDEMIA
DK2892556T3 (da) Sammensætninger og fremgangsmåder til behandling af sygdomme